| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1.49 MB | Adobe PDF |
Abstract(s)
Introdução: Quase dois anos após a emergência de um novo coronavírus, mantêm-se
diversas incertezas e preocupações sobre esta estirpe (SARS-CoV-2) e a doença por si
causada, a COVID-19. No que diz respeito à Reumatologia, um desafio particular passa
pelos pacientes com Doenças Reumáticas Inflamatórias (DRI), cuja patologia e
tratamento biotecnológico associado poderão ter impacto no curso da infeção por este
vírus.
Objetivos: Visto que a informação, relativamente a este tema, é ainda escassa, este
trabalho visa a implementação de um sistema de registo de dados de todos os pacientes
reumáticos seguidos e medicados com terapêutica biotecnológica, com foco na infeção
por SARS-CoV-2 e sua vacinação, de modo a obter um melhor entendimento da
repercussão que a COVID-19 tem em pacientes com DRI.
Métodos: Dados referentes ao período de março de 2020 a dezembro de 2021 foram
recolhidos através da consulta de processos clínicos de doentes sob tratamento
biotecnológico e analisados no contexto de um estudo observacional e retrospetivo.
Resultados: Foi desenvolvido um registo reumatológico com pacientes sob tratamento
biotecnológico, com ênfase na COVID-19 e respetiva vacinação (registo BioteCoviVac).
Os dados consistiram em informações demográficas, clínicas e relativas à infeção por
SARS-CoV-2, em pacientes seguidos numa pequena unidade de Reumatologia.
Conclusão: É esperado que este registo de dados facilite a avaliação dos pacientes em
estudo e melhore os resultados obtidos após a exposição ao vírus SARS-CoV-2. Este
registo poderá harmonizar a informação relativa ao tratamento, outcomes e bem-estar
dos doentes seguidos ao longo do tempo, assim como identificar as melhores práticas e
reforçar recomendações baseadas em evidência para a gestão deste grupo de pacientes,
durante a pandemia.
Introduction: Almost two years after the emergence of a novel coronavirus, there remain many uncertainties and worries about SARS-CoV-2 and the disease it causes, called coronavirus disease (COVID-19). In what concerns Rheumatology, a particular challenge are patients with Inflammatory Rheumatic Diseases, whose infirmity and associated biotechnological treatment may have an impact on the course of infection by this virus. Objective: As information on this theme is still scarce, this paper aims to implement a data collection system for all rheumatic patients treated and followed with biotechnological treatment with a focus on SARS-CoV-2 infection and its vaccination, in order to better understand the impact COVID-19 has on people with Inflammatory Rheumatic Diseases. Method: The data were collected through the consultation of clinical files for the period of march 2020 and december 2021 and processed in the context of a retrospective and observational study. Results: A rheumatologic registry with patients treated with biotechnological treatment, with an emphasis on COVID-19 and vaccination, was developed (BioteCoviVac registry). Data consisted of demographic, clinical, and supporting information about SARS-CoV-2 - infection and vaccination - among rheumatology outpatients followed in a small rheumatology Unit. Conclusion: It is hoped that the current data registry will facilitate patient evaluation and improve the outcomes after SARS-Cov-2 exposure. The registry can harmonize data about the treatment, outcomes, and well-being of patients who receive care over time, as well as identify best practices and reinforce evidence-based recommendations for the management of this group of patients, during the pandemic.
Introduction: Almost two years after the emergence of a novel coronavirus, there remain many uncertainties and worries about SARS-CoV-2 and the disease it causes, called coronavirus disease (COVID-19). In what concerns Rheumatology, a particular challenge are patients with Inflammatory Rheumatic Diseases, whose infirmity and associated biotechnological treatment may have an impact on the course of infection by this virus. Objective: As information on this theme is still scarce, this paper aims to implement a data collection system for all rheumatic patients treated and followed with biotechnological treatment with a focus on SARS-CoV-2 infection and its vaccination, in order to better understand the impact COVID-19 has on people with Inflammatory Rheumatic Diseases. Method: The data were collected through the consultation of clinical files for the period of march 2020 and december 2021 and processed in the context of a retrospective and observational study. Results: A rheumatologic registry with patients treated with biotechnological treatment, with an emphasis on COVID-19 and vaccination, was developed (BioteCoviVac registry). Data consisted of demographic, clinical, and supporting information about SARS-CoV-2 - infection and vaccination - among rheumatology outpatients followed in a small rheumatology Unit. Conclusion: It is hoped that the current data registry will facilitate patient evaluation and improve the outcomes after SARS-Cov-2 exposure. The registry can harmonize data about the treatment, outcomes, and well-being of patients who receive care over time, as well as identify best practices and reinforce evidence-based recommendations for the management of this group of patients, during the pandemic.
Description
Keywords
Covid-19 Doenças Reumáticas Inflamatórias Reumatologia Terapêutica Biotecnológica